Karyopharm Therapeutics Inc (KPTI)
Karyopharm Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on drugs that act through nuclear export inhibition for the treatment of cancer and other diseases in the United States. The company develops small-molecule SINE compounds designed to inhibit exportin 1 (XPO1), and its portfolio includes XPOVIO and selinexor-based programs targeting hematologic and solid tumor malignancies. XPOVIO is approved for use in multiple myeloma and relapsed or refractory diffuse large B-cell lymphoma, while selinexor is being studied across indications such as multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL. Karyopharm is also advancing eltanexor for certain myeloproliferative neoplasms and TP53 wild-type solid tumors. The company has collaboration and license agreements with Menarini Group, Antengene Therapeutics Limited, FORUS Therapeutics Inc., and Bristol Myers Squibb. Incorporated in 2008, Karyopharm is headquartered in Newton, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-KPTI
|
$8.62
|
7.3% Upside
|
Fair
|
$13.50
|
68.1% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-0.9x
|
-0.7x
|
1.2x
|
169.3 M
|
394.2 M
|
64.2%
|
65.4%
|
-19.6
|
—
|
30.3%
|
